Drug Database
Back to search

Netherlands· NL-916809f97cc3

Iqirvo 80 mg filmomhulde tabletten

A elafibranor product containing elafibranor, registered in Netherlands by Ipsen Pharma. The same ATC class is registered in 12 of our 19 countries.

ATC A05AX06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedIqirvo 80 mg filmomhulde tablettenATCA05AX06REGISTER NO.NL-916809f97cc3PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about elafibranorAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Elafibranor is registered in 12 of 19 countries.

Countries holding a registration under ATC A05AX06 (elafibranor), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search elafibranor products by name

Elafibranor · ATC A05AX06

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ELAFIBRANOR
Manufacturer
Ipsen Pharma
Country
Netherlands (NL)
ATC code
A05AX06
ATC class
Elafibranor
Defined daily dose
80 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1855

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Elafibranor in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All elafibranor products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Iqirvo
  • Liechtenstein · Iqirvo
  • Norway · Iqirvo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eb118037-e07a-4ae4-b3ae-84a7e3d4df50
GET /v1/drugs/eb118037-e07a-4ae4-b3ae-84a7e3d4df50?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/iqirvo-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Elafibranor",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132414",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "POVIDON K 30 (E 1201)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ELAFIBRANOR"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/09/19",
  "procedure_number": "EMEA/H/C/006231",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1855",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about elafibranor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console